As major U.S. stock indexes recently experienced slight declines amid a mix of earnings reports and anticipation of tech giant performances, investors might find potential opportunities in undervalued stocks. In the current climate, where small-cap stocks show resilience and market volatility persists, identifying stocks trading below their intrinsic values could offer attractive entry points for those looking to diversify or enhance their portfolios.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Noble (NYSE:NE) $47.64 $93.49 49% Oddity Tech (NasdaqGM:ODD) $39.67 $78.85 49.7% Sachem Capital (NYSEAM:SACH) $2.69 $5.35 49.7% Fluence Energy (NasdaqGS:FLNC) $16.14 $31.77 49.2% AppLovin (NasdaqGS:APP) $83.81 $164.66 49.1% Duckhorn Portfolio (NYSE:NAPA) $7.26 $14.44 49.7% Tompkins Financial (NYSEAM:TMP) $60.40 $118.89 49.2% Sea (NYSE:SE) $66.98 $133.89 50% Smartsheet (NYSE:SMAR) $48.45 $95.82 49.4% Harvard Bioscience (NasdaqGM:HBIO) $3.30 $6.56 49.7%

Click here to see the full list of 186 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Vertex Pharmaceuticals

Overview: Vertex Pharmaceuticals Incorporated is a biotechnology firm focused on developing and commercializing therapies for cystic fibrosis, with a market capitalization of approximately $127.97 billion.

Operations: The company generates its revenue primarily from its pharmaceuticals segment, totaling approximately $10.19 billion.

Estimated Discount To Fair Value: 38.5%

Vertex Pharmaceuticals, priced at US$490.32, is significantly undervalued by our cash flow-based valuation, suggesting a fair value of US$797.66. This indicates a potential undervaluation of 38.5%. The company's return on equity is expected to be robust at 21.7% in three years, outpacing forecasts for the broader U.S. market. Although earnings growth projections are not exceptional, they remain solid at 15.9% annually, slightly ahead of the market's 14.8%. Recent strategic alliances aim to enhance its drug development capabilities through genomics and machine learning until 2026, potentially bolstering future performance.

In light of our recent growth report, it seems possible that Vertex Pharmaceuticals' financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of Vertex Pharmaceuticals. NasdaqGS:VRTX Discounted Cash Flow as at Jul 2024

Truist Financial

Overview: Truist Financial Corporation is a financial services company that offers banking and trust services in the Southeastern and Mid-Atlantic United States, with a market capitalization of approximately $58.59 billion.



Operations: The company generates revenue primarily from banking and trust services across the Southeastern and Mid-Atlantic regions of the United States.

Estimated Discount To Fair Value: 34.4%

Truist Financial, trading at US$44.15, is assessed to be well below its fair value of US$67.33, indicating a substantial undervaluation of 34.4%. Despite a low forecasted return on equity of 9.4% in three years, the company is expected to grow its revenue and profits significantly above the market average at 17.7% and 61.12% per year respectively. Recent dividends affirmations and a large US$5 billion share buyback program reflect confidence in financial stability but also highlight current earnings coverage concerns for dividends.

Our earnings growth report unveils the potential for significant increases in Truist Financial's future results. Unlock comprehensive insights into our analysis of Truist Financial stock in this financial health report. NYSE:TFC Discounted Cash Flow as at Jul 2024

Vertiv Holdings Co

Overview: Vertiv Holdings Co (NYSE: VRT) operates globally, designing, manufacturing, and servicing critical digital infrastructure technologies for data centers, communication networks, and various industrial sectors with a market capitalization of approximately $32.89 billion.

Operations: Vertiv's revenue is segmented into the Americas ($3.95 billion), Asia Pacific ($1.64 billion), and Europe, the Middle East & Africa ($1.83 billion).

Estimated Discount To Fair Value: 21.1%

Vertiv Holdings Co, currently priced at US$91, appears undervalued based on cash flows with a fair value estimated at US$115.29. Despite recent drops from several Russell indexes, Vertiv's strategic addition of ZincFive’s nickel-zinc batteries for data center backup power underscores its innovative edge and commitment to sustainability. Expected to outpace the U.S. market with a 9.6% annual revenue growth and 30.3% earnings growth, it also boasts a projected very high return on equity of 58.3% in three years, although it carries high debt levels.

Our growth report here indicates Vertiv Holdings Co may be poised for an improving outlook. Delve into the full analysis health report here for a deeper understanding of Vertiv Holdings Co. NYSE:VRT Discounted Cash Flow as at Jul 2024

Key Takeaways

Explore the 186 names from our Undervalued US Stocks Based On Cash Flows screener here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Ready To Venture Into Other Investment Styles?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:VRTXNYSE:TFC and NYSE:VRT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

()